---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053940"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-08-06T12:49:15+00:00"
generated_at: "2026-08-06T12:50:07.578425+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track

## Summary
- Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.
- Completed enrollment in MAD portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data expected Q4 2026.
- Proposed merger with Clywedog expected to close H2 2026; combined company to trade as CLYD.
- Received Nasdaq extension to Dec 28, 2026 to regain bid price compliance; ADS transferred to Nasdaq Capital Market.
- R&D expenses $3.9M (up from $3.6M Q1); G&A expenses $7.1M (up from $2.5M) due to FX losses and professional fees.

## SEC filing metadata
- accession: 0001628280-26-053940
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-08-06T12:49:15+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/0001628280-26-053940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053940
- JSON: https://secwatch.observer/filing/0001628280-26-053940.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.